Safety of CETP inhibition

Current Opinion in Lipidology

Volumn 23, Issue 6, 2012, Pages 518-524

  Duivenvoorden, Raphaël ^a,b   Fayad, Zahi A ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

cardiovascular disease; cholesterol ester transfer protein; high density lipoprotein cholesterol

Indexed keywords

ALDOSTERONE; ANACETRAPIB; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; EVACETRAPIB; FLUORODEOXYGLUCOSE F 18; PLACEBO; POTASSIUM; SODIUM; TORCETRAPIB; TRIACYLGLYCEROL;

ALDOSTERONE BLOOD LEVEL; ATHEROSCLEROSIS; BLOOD PRESSURE; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG SAFETY; ENDOTHELIUM; FATALITY; HEART INFARCTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; ULTRASOUND; UNSTABLE ANGINA PECTORIS;

ANIMALS; BENZODIAZEPINES; CHOLESTEROL ESTER TRANSFER PROTEINS; HUMANS; OXAZOLIDINONES; QUINOLINES; SAFETY; SULFHYDRYL COMPOUNDS;

EID: 84870064666     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32835916b3     Document Type: Review

References (39)

1. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 2005; 46:1225-1228. (Pubitemid 41615541)
2. Vergeer M, Holleboom AG, Kastelein JJ, Kuivenhoven JA. The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? J Lipid Res 2010; 51:2058-2073.
3. Zhang L, Yan F, Zhang S, et al. Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein. Nat Chem Biol 2012; 8:342-349. A study that unravelled the mechanism by which CETP transfers cholesterol ester and triglycerides.
4. Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res 2006; 47:537-552. (Pubitemid 43345595)
5. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356:1304-1316. (Pubitemid 46513296)
6. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356:1620-1630. (Pubitemid 46631671)
7. Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, doubleblind trial. Lancet 2007; 370:153-160. (Pubitemid 47042895)
8. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-2122. (Pubitemid 350146106)
9. Lüscher TF, Taddei S, Kaski JC, et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J 2012; 33:857-865. A randomized placebo controlled trial that investigated the effect of dalectrapib on endothelial function and blood pressure.
10. Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel noninvasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011; 378:1547-1559. A randomized placebo controlled trial that investigated the effect of dalectrapib on atherosclerosis progression measured by carotid MRI and vessel wall inflammation measured by 18F-FDG PET/C.T.
11. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011; 306:2099-2109.
12. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363:2406-2415.
13. Tobis JM, Mallery J, Mahon D, et al. Intravascular ultrasound imaging of human coronary arteries in vivo. Analysis of tissue characterizations with comparison to in vitro histological specimens. Circulation 1991; 83:913-926.
14. Nicholls SJ, Tuzcu EM, Brennan DM, et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 2008; 118:2506-2514.
15. Duivenvoorden R, Nederveen AJ, de Groot E, Kastelein JJ. Atherosclerosis imaging as a benchmark in the development of novel cardiovasular drugs. Curr Opin Lipidol 2007; 18:613-621. (Pubitemid 350098565)
16. Vergeer M, Bots ML, van Leuven SI, et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 2008; 118:2515-2522.
17. Hillaert MA, Lentjes EG, Beygui F, et al. Measuring and targeting aldosterone and renin in atherosclerosis: a review of clinical data. Am Heart J 2011; 162:585-596.
18. Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008; 154:1465-1473.
19. Simic B, Hermann M, Shaw SG, et al. Torcetrapib impairs endothelial function in hypertension. Eur Heart J 2012; 33:1615-1624.
20. Sofat R, Hingorani AD, Smeeth L, et al. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation 2010; 121:52-62.
21. Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000; 406:203-207. (Pubitemid 30469005)
22. Huang Z, Inazu A, Nohara A, et al. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci 2002; 103:587-594. (Pubitemid 36005711)
23. Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains efficient prebeta-HDL formation and increases reverse cholesterol transport. J Lipid Res 2010; 51:3443-3454.
24. Niesor EJ, von der Marck E, Brousse M, Maugeais C. Inhibition of cholesteryl ester transfer protein (CETP): different in vitro characteristics of RO4607381/JTT-705 and torcetrapib (TOR). Atherosclerosis 2008; 199:231.
25. Stroes ES, Kastelein JJ, Bé nardeau A, et al. Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats. Br J Pharmacol 2009; 158:1763-1770.
26. Kastelein JJ, Duivenvoorden R, Deanfield J, et al. Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation. Curr Med Res Opin 2011; 27:141-150.
27. Fayad ZA, Mani V, Woodward M, et al. Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Am Heart J 2011; 162:214-221.
28. Yeboah J, Folsom AR, Burke GL, et al. Predictive value of brachial 573 flowmediated dilation for incident cardiovascular events in a 574 populationbased study: the multiethnic study of atherosclerosis. Circulation 2009; 120:502-509.
29. Yeboah J, Burke GL, Crouse JR, et al. Relationship between 578 brachial flow-mediated dilation and carotid intima-media thickness in an elderly cohort: the Cardiovascular Health Study. Atherosclerosis 2008; 197:840-845. (Pubitemid 351417883)
30. Hovingh GK, de Groot E, van der Steeg W, et al. Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol 2005; 16:139-145. (Pubitemid 40515887)
31. Spieker LE, Sudano I, Hürlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002; 105: 1399-1402. (Pubitemid 34263266)
32. Nieuwdorp M, Vergeer M, Bisoendial RJ, et al. Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus. Diabetologia 2008; 51:1081-1084.
33. Tahara N, Kai H, Yamagishi S, et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol 2007; 49:1533-1539. (Pubitemid 46517964)
34. Ward MR, Pasterkamp G, Yeung AC, Borst C. Arterial remodeling: mechanisms and clinical implications. Circulation 2000; 102:1186-1191.
35. Duivenvoorden R, Holleboom AG, van den Bogaard B, et al. Carriers of lecithin cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3. 0-T magnetic resonance imaging. J Am Coll Cardiol 2011; 58:2481-2487.
36. Bochem AE, van Wijk DF, Duivenvoorden R, et al. Mutations in ABCA1 are associated with increased atherosclerosis: a 3.0 tesla MRI study. Circulation. 2011; 21:SUPPL. A12617.
37. Lee JM, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009; 54:1787-1794.
38. Schwartz GG, Olsson AG, Ballantyne CM, et al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009; 158:896-901.
39. Roche, Inc. Roche provides update on Phase III study of dalcetrapib [press release]. http://www.roche.com/media/media-releases/med-cor-2012-05-07. htm. [Accessed 12 May 2012].